Asieris Reports the P-III Study Results of APL-1702 for Treating Cervical High-Grade Squamous Intraepithelial Lesions
Shots:
- Asieris has presented results from the P-III clinical evaluation of APL-1702’s safety & effectiveness vs PBO to treat cervical HSIL having the 1EP as proportion of responders at 6mos. post initial treatment at the 2024 EUROGIN Congress as well as the SGO Annual Meeting
- The study demonstrated an improvement of 89.4% in response rate and a 103.9% increase in high-risk HPV16 and/or HPV18 clearance rate (31.4% vs 15.4%) in APL-1702 vs PBO arm
- APL-1702 (Cevira) is a photodynamic drug-device conjugate designed for non-surgical treatment of high-grade precancerous cervical lesions
Ref: Asieris | Image: Asieris
Related News:- Asieris Receives the TGA’s Approval to Initiate P-I Trial for APL-2301 to Treat Acinetobacter baumannii Infection
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
